INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2017. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $296,163 | -46.1% | 6,365 | -70.3% | 0.00% | -66.7% |
| Q2 2020 | $549,000 | -34.2% | 21,400 | -60.5% | 0.01% | -33.3% |
| Q1 2020 | $834,000 | -99.7% | 54,199 | -99.2% | 0.01% | -99.5% |
| Q4 2019 | $241,225,000 | +7767.7% | 7,030,748 | +1612.7% | 1.87% | +8021.7% |
| Q3 2019 | $3,066,000 | +239.9% | 410,499 | +490.5% | 0.02% | +228.6% |
| Q2 2019 | $902,000 | -85.4% | 69,512 | -82.3% | 0.01% | -83.3% |
| Q3 2017 | $6,183,000 | – | 391,792 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |